glp.1 patches image.cfm?name=XI-B08-0042-01.jpg&id=912602 Things to Know About GLP-1

Patients enrolled in Medicare who are diagnosed with obesity and related comorbidities will have a co-pay of $50 per month for Wegovy and Zepbound

Bottom line: Fiber-forward, prebiotic approaches appear to be the most reliable microbiome-based strategy for managing metabolic disease

The extent of weight loss varies by productfor example, semaglutide 2.4mg (Wegovy) has shown average weight loss of approximately 15% after 68 weeks in clinical trials, while liraglutide 3mg (Saxenda) typically achieves 5-8% weight loss

Peptide engineering is further advancing this concept by creating single agents possessing activity at more than one pharmacologic target

[DOI] [PMC free article] [PubMed] [Google Scholar] 24.Lucas-Herald A.K., Alves-Lopes R., Montezano A.C., Ahmed S.F., Touyz R.M